The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Employment - Sensei Biotherapeutics
Leadership - Sensei Biotherapeutics
Stock and Other Ownership Interests - Sensei Biotherapeutics; X4 Pharma
Travel, Accommodations, Expenses - Sensei Biotherapeutics
Safety/efficacy of a phase I/II study of SNS-301 added to pembrolizumab in patients with ASPH+ locally advanced unresectable or metastatic/recurrent squamous cell carcinoma of the head and neck (SCCHN).
 
William Smith
Research Funding - NOCCR/AMR
 
John Celebi
No Relationships to Disclose
 
Robert Pierce
Leadership - Alvaxa Biosciences (I)
Stock and Other Ownership Interests - Alvaxa Biosciences; Calithera Biosciences (I); Celgene (I); Five Prime Therapeutics (I); Immunomic Therapeutics; OncoSec; Sensei Biotherapeutics
Consulting or Advisory Role - Abbvie; Apros Therapeutics (I); Calithera Biosciences; Genexine (I); Ideaya Biosciences (I); IgM Biosciences (I); Immune Design (I); Juno Therapeutics (I); Neoleukin Therapeutics; Nkarta (I); Pulse Biosciences; Seagen (I)
Research Funding - AstraZeneca/MedImmune (Inst); Exicure (Inst); Immunomic Therapeutics (Inst); Incyte (Inst); Juno Therapeutics (Inst); Minerva Neurosciences (Inst); Pulse Biosciences (Inst); Sensei Biotherapeutics (Inst); X4 Pharma (Inst)
Travel, Accommodations, Expenses - Immunomic Therapeutics; Immunomic Therapeutics; Pulse Biosciences; Sensei Biotherapeutics
 
Alice Drumheller
Employment - Macrogenics; Sensei Biotherapeutics
Stock and Other Ownership Interests - Allogene Therapeutics; Inovio Pharmaceuticals; Macrogenics; Merrimack; Sensei Biotherapeutics
Travel, Accommodations, Expenses - Sensei Biotherapeutics
 
Ildiko Csiki
Employment - Inovio Pharmaceuticals; Sensei Biotherapeutics
Leadership - Sensei Biotherapeutics
Stock and Other Ownership Interests - Sensei Biotherapeutics
Consulting or Advisory Role - Sensei Biotherapeutics
Travel, Accommodations, Expenses - Inovio Pharmaceuticals; Sensei Biotherapeutics
 
Alain Patrick Algazi
Stock and Other Ownership Interests - OncoSec; Valitor
Consulting or Advisory Role - Array BioPharma; OncoSec; Regeneron; Valitor
Research Funding - Acerta Pharma (Inst); Amgen (Inst); AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); Dynavax Technologies (Inst); Genentech (Inst); Idera (Inst); Incyte (Inst); Merck (Inst); Novartis (Inst); Oncosec (Inst); OncoSec (Inst); Sensei Biotherapeutics (Inst); Tessa Therapeutics (Inst)
Travel, Accommodations, Expenses - OncoSec
(OPTIONAL) Uncompensated Relationships - Merck; Sensei Biotherapeutics